# Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

> **NCT05900895** · PHASE1 · RECRUITING · sponsor: **Mary D Chamberlin** · enrollment: 6 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** 17b-estradiol

## Key facts

- **NCT ID:** NCT05900895
- **Lead sponsor:** Mary D Chamberlin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-15
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05900895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05900895, "Estradiol Plus Olaparib for Breast Cancer (PHOEBE)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05900895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*